On September 23, Abivax S.A. fell 5.28% in regular trading, trading at 93.18 USD/share, with turnover of approximately $114 million, as the stock continued to face heavy selling pressure following its H1 earnings release.

Abivax S.A. reported H1 losses of $(2.43) per share, missing the analyst consensus estimate of $(1.08) by 125%, and widening 65.31% from the year-ago loss of $(1.47) per share. While revenue of $2.959 million beat the $1.860 million estimate, the magnitude of the earnings miss triggered significant negative sentiment. Wedbush cut its price target to $118 from $160 while maintaining a Neutral rating, and Truist lowered its target to $151, though the average analyst rating remains Buy with a mean target of $164.20.

Adding to market uncertainty, the company announced that Chief Medical Officer Fabio Cataldi will depart in Q4, with Chris Rabbat succeeding him. The management transition comes at a critical juncture as Abivax S.A. plans to submit its New Drug Application for lead candidate obefazimod in ulcerative colitis before year-end.

Abivax S.A. is a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate immune responses in chronic inflammatory diseases.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)